New Two-Drug attack on advanced lung cancer enters major trial
NCT ID NCT07183189
Summary
This study is testing whether adding a new drug called SHR-A2009 to an existing lung cancer drug (aumolertinib) works better than using aumolertinib alone. It is for adults with a specific type of advanced lung cancer who have not yet received treatment. The main goal is to see if the combination can keep the cancer from growing for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact
Conditions
Explore the condition pages connected to this study.